Efficacy and tolerability of ethionamide versus prothionamide: a systematic review.
MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease, Paris, France The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland These authors contributed equally.
Anna
A
Scardigli
MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease, Paris, France Pneumology Dept, General Hospital of Gran Canaria "Dr. Negrin", Las Palmas, Spain These authors contributed equally.
Jose A
JA
Caminero
Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari, Medical Education and Professional Development Unit, Sassari, Italy These authors contributed equally.
Giovanni
G
Sotgiu
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy.
Rosella
R
Centis
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland.
Lia
L
D'Ambrosio
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy giovannibattista.migliori@fsm.it.
Giovanni Battista
GB
Migliori
D000995:Antitubercular Agents / Q000627:therapeutic use*; D005000:Ethionamide / Q000627:therapeutic use*; D006801:Humans; D011515:Prothionamide / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D011515:Prothionamide; D005000:Ethionamide